about
Development of polymeric micelles for targeting intractable cancersIdentification of a candidate single-nucleotide polymorphism related to chemotherapeutic response through a combination of knowledge-based algorithm and hypothesis-free genomic data.The significance of microscopic mass spectrometry with high resolution in the visualisation of drug distribution.Enhanced antitumor effect of anti-tissue factor antibody-conjugated epirubicin-incorporating micelles in xenograft models.Vascular bursts enhance permeability of tumour blood vessels and improve nanoparticle delivery.Imaging mass spectrometry for the precise design of antibody-drug conjugates.Tumour imaging by the detection of fibrin clots in tumour stroma using an anti-fibrin Fab fragment.Utility of epirubicin-incorporating micelles tagged with anti-tissue factor antibody clone with no anticoagulant effect.Antitumor effect of antitissue factor antibody-MMAE conjugate in human pancreatic tumor xenograftsPhase I study of NK105, a nanomicellar paclitaxel formulation, administered on a weekly schedule in patients with solid tumors.Effect of combined treatment with micelle-incorporated cisplatin (NC-6004) and S-1 on human gastric cancer xenografts.High expression of miR-181c as a predictive marker of recurrence in stage II colorectal cancer.Preclinical efficacy of Sym004, novel anti-EGFR antibody mixture, in esophageal squamous cell carcinoma cell lines.Role of SLC6A6 in promoting the survival and multidrug resistance of colorectal cancer.New molecular diagnosis and screening methods for colorectal cancer using fecal protein, DNA and RNA.The drug discovery by nanomedicine and its clinical experience.General considerations regarding the in vitro and in vivo properties of block copolymer micelle products and their evaluation.Feasibility study of the Fab fragment of a monoclonal antibody against tissue factor as a diagnostic tool.Antibody fragment-conjugated polymeric micelles incorporating platinum drugs for targeted therapy of pancreatic cancer.Marked antitumor effect of NK012, a SN-38-incorporating micelle formulation, in a newly developed mouse model of liver metastasis resulting from gastric cancer.Effect of combined treatment with the epirubicin-incorporating micelles (NC-6300) and 1,2-diaminocyclohexane platinum (II)-incorporating micelles (NC-4016) on a human gastric cancer model.Immunoregulation by IL-7R-targeting antibody-drug conjugates: overcoming steroid-resistance in cancer and autoimmune disease.Development of Antibody-Drug Conjugates Using DDS and Molecular Imaging.Molecular imaging using an anti-human tissue factor monoclonal antibody in an orthotopic glioma xenograft modelDistal promoter regions are responsible for differential regulation of human orosomucoid-1 and -2 gene expression and acute phase responses.Fecal miR-106a is a useful marker for colorectal cancer patients with false-negative results in immunochemical fecal occult blood test.Targeting anticoagulant protein S to improve hemostasis in hemophilia.Development of ADCs Using Molecular Imaging.Cancer Stromal Targeting Therapy.Collagen type I induces EGFR-TKI resistance in EGFR-mutated cancer cells via mTOR activation through Akt-independent pathway.Tuned Density of Anti-Tissue Factor Antibody Fragment onto siRNA-Loaded Polyion Complex Micelles for Optimizing Targetability into Pancreatic Cancer Cells.A phase II study of NK012, a polymeric micelle formulation of SN-38, in unresectable, metastatic or recurrent colorectal cancer patientsChemotherapy payload of anti-insoluble fibrin antibody-drug conjugate is released specifically upon binding to fibrinNear-infrared photoimmunotherapy of pancreatic cancer using an indocyanine green-labeled anti-tissue factor antibodySignificant antitumor effect of an antibody against TMEM180, a new colorectal cancer-specific moleculeInfluence of the dissociation rate constant on the intra-tumor distribution of antibody-drug conjugate against tissue factorTopological analysis of TMEM180, a newly identified membrane protein that is highly expressed in colorectal cancer cellsSerum level of octanoic acid predicts the efficacy of chemotherapy for colorectal cancerAnti‑tissue factor antibody‑mediated immuno‑SPECT imaging of tissue factor expression in mouse models of pancreatic cancerEvaluation of the antitumor mechanism of antibody-drug conjugates against tissue factor in stroma-rich allograft models
P50
Q26749611-88BE0748-ECD1-4296-AC36-3CBEB7D5C0F1Q30652586-BBD44288-C680-44D7-94EE-708A9C41CBDBQ35025984-CE0A2CA5-C3EB-49E9-B511-A0C94A31F4CDQ35674222-EFD525ED-84F8-45B7-8623-F42996FE3FA2Q35924007-239A08D5-6EB4-4F0C-98D2-99C3027F0A1DQ35995175-8DB4648F-C4A4-414E-95D7-D200C421ED09Q36724890-1621AB23-A716-408B-9E8C-AC7B1D953F61Q36746313-2FB326FD-0E31-4220-A842-1BAFD91AEA4CQ37257515-29CA51FE-3F6E-4025-BD4E-55042A5B04FCQ37399257-81352421-FFC1-40F5-A050-7F186697E882Q37581660-176E3F8C-F56F-48F5-A26E-1132A572CC9DQ37701707-5D44F21B-659F-4584-AE64-8177D4F2C919Q37706868-CF898DD3-4C59-4BC8-8427-13E30E1DBF1EQ37733017-3B398097-B077-4015-9482-2CF429C7E9AFQ38168867-12D120F8-CC96-491E-9D78-D322805921D2Q38206349-9FD9C3FB-F101-4F18-9117-56E7D75B2D10Q38483265-222D90FC-A0D1-4A6E-BC24-FB1F544897D9Q38825452-CBD2DF1B-3A43-4888-9F98-87EF8E1E66E7Q38932075-2FEB159F-9860-4F03-AFE9-D6D21802F4AFQ39028548-EE86D35F-CB39-43D6-B3B1-4CE6EFC62B99Q39041944-F4645256-7649-4EAA-BE43-2618E0C3A8B0Q41636928-0F6D961B-7C9D-454D-855F-FD026FE8E024Q41670098-35ECC500-DB8D-4DBF-8C2C-41DCA4CDE59DQ42364589-CA67CD2D-267B-4FE6-867F-86E34289DE62Q42451857-72D84159-7E88-48A2-8134-A14EFDBEE316Q44126830-05C1F4CF-D29E-441A-955F-7EB80D1D910CQ47215919-82581490-1B6A-48EF-B89C-AC5AB976D18DQ50440702-1C2C7E2F-34D8-4AA5-8540-FB35EE22628DQ50440705-E1EE38BA-4D2C-408F-9791-B597B7F949C6Q52716291-2B1D21F8-EB1F-4799-A904-9FB635ACDF8DQ54109430-9899BF1C-9994-4143-B892-3EC490A687BDQ57025199-59D0F304-9414-4464-805A-A3563F45F2E5Q58705418-79BECA83-AA2B-4885-9131-F73756D637F4Q60929964-B1719246-E029-4FAC-8C45-D8478F3E6532Q61805740-03CF06C8-D89B-4654-B28C-6D741CAC9BFAQ89115705-00C709CC-D225-4DE0-9274-8FD18ED9104DQ90728520-5F960BAF-C6F9-47AD-974B-10282B0B6CD6Q91101226-B3A3F7BE-8BAC-4BE7-B6DA-136D473A9B8AQ91998826-A0C762DF-A661-4FF6-93B1-9BE4298F586DQ92202339-F96A8ADC-D3A2-41D9-8A4F-EDE10B2EC362
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Yasuhiro Matsumura
@en
Yasuhiro Matsumura
@nl
type
label
Yasuhiro Matsumura
@en
Yasuhiro Matsumura
@nl
prefLabel
Yasuhiro Matsumura
@en
Yasuhiro Matsumura
@nl
P31
P496
0000-0003-4331-8177